Skip to main content

Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents

CNS Drugs volume 16, pages 139–144 (2002)Cite this article

Abstract

Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day. However, steady-state plasma fluvoxamine concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents; thus, the maximum fluvoxamine dosage recommended for children is 200 mg/day.

Fluvoxamine (50 to 300 mg/day) for 8 to 16 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) [measured across multiple assessment scales] compared with placebo in a well controlled trial in paediatric patients (n = 120) or from baseline in noncomparative trials in adolescent (n = 20) or paediatric (n = 16) patients. Improvements with fluvoxamine (up to 200 mg/day) were observed for up to 1 year in 98 patients with OCD in a noncomparative trial. The drug (up to 250 or 300 mg/day) also improved symptoms of anxiety compared with placebo in an 8-week well controlled trial in 128 paediatric patients with social phobia, separation anxiety disorder or generalised anxiety disorder (GAD).

Fluvoxamine (50 to 300 mg/day) appears to be well tolerated in paediatric 1 The full text of this article was published in Paediatric Drugs 2001; 3 (10): 763–781. patients, with most adverse events with the drug (except abdominal discomfort, which occurred more often in patients receiving fluvoxamine) occurring with a similar incidence to those with placebo. The most common adverse events involved the CNS or gastrointestinal system. Most adverse events reported by paediatric patients with OCD were similar to those reported by adults.

In conclusion, fluvoxamine is generally well tolerated and has demonstrated short-term efficacy compared with placebo in the treatment of OCD, and social phobia, separation anxiety disorder or GAD in well controlled trials in paediatric patients. Reductions in symptoms of anxiety with fluvoxamine have been observed for up to 1 year in children and adolescents with OCD. However, there are currently no comparative trials of fluvoxamine with other pharmacological agents. In the absence of such trials, current consensus opinion recommends that when pharmacotherapy is indicated, fluvoxamine, like other SSRIs, can be used as first-line treatment for anxiety disorders, particularly OCD, in paediatric patients. However, direct comparisons are required to assess the relative efficacy and tolerability of pharmacological agents in order to make firm recommendations for the treatment of anxiety disorders in this patient group.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Claassen V. Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 1983; 15: 349–55

    Article  CAS  Google Scholar 

  2. Hyttel J, Larsen J-J. Serotonin-selective antidepressants. Acta Pharmacol Toxicol (Copenhagen) 1985; 56(1): 146–53

    Article  CAS  Google Scholar 

  3. Claassen V, Davies JE, Hertting G, et al. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 1977; 60: 505–16

    PubMed  Article  CAS  Google Scholar 

  4. Constantinidis J, Dick P, Tissot R. Antidepressants and serotonin neurons of the raphe. Neuropsychobiology 1981; 7: 113–21

    PubMed  Article  CAS  Google Scholar 

  5. Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine. Br J Pharmacol 1992; 105: 941–6

    PubMed  Article  CAS  Google Scholar 

  6. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 1992; 229: 101–3

    PubMed  Article  CAS  Google Scholar 

  7. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34

    PubMed  Article  CAS  Google Scholar 

  8. Hall H, Sällemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol (Copenhagen) 1984; 54: 379–84

    Article  CAS  Google Scholar 

  9. Richelson E, Nelson A. Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 1984; 230: 94–102

    PubMed  CAS  Google Scholar 

  10. Alexander BS, Wood MD. [3HJ8-OH-DPAT labels the 5-hydroxytryptamine uptake recognition site and the 5-HT1A binding site in the rat striatum. J Pharm Pharmacol 1988; 40: 888–91

    PubMed  Article  CAS  Google Scholar 

  11. Jenck F, Moreau J-L, Mutel V, et al. Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 1993; 231: 223–9

    PubMed  Article  CAS  Google Scholar 

  12. Wong DT, Bymaster FP, Reid LR, et al. Fluoxetine and two other serotonin reuptake inhibitors without affinity for neuronal receptors. Biochem Pharmacol 1983; 32: 1287–93

    PubMed  Article  CAS  Google Scholar 

  13. Jenck F, Broekkamp CLE, van Delft AML. The effect of antidepressants on aversive periaqueductal gray stimulation in rats. Eur J Pharmacol 1990; 177: 201–4

    PubMed  Article  CAS  Google Scholar 

  14. Olivier B, Bosch L, van Hest A, et al. Preclinical evidence on the psychotrophic profile of fluvoxamine. Pharmacopsychiatry 1993 May; 26: 2–9

    PubMed  Article  Google Scholar 

  15. Njung’e K, Handley SL. Effects of 5-HT uptake inhibitors, agonists and antagonists on burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 1991; 104: 105–12

    PubMed  Article  Google Scholar 

  16. Woods A, Smith C, Szewczak M, et al. Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl) 1993; 112: 195–8

    Article  CAS  Google Scholar 

  17. Wilson WH, Higano H, Papadatos Y, et al. A double-blind placebocontrolled study to compare the autonomic effects of fluvoxamine with those of amitriptyline and doxepin in healthy volunteers. Br J Clin Pharmacol 1983; 15: 385–92

    Article  CAS  Google Scholar 

  18. Robinson JF, Doogan DP. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. Br J Clin Pharmacol 1982; 14: 805–8

    PubMed  Article  CAS  Google Scholar 

  19. Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246: 1–6

    PubMed  Article  CAS  Google Scholar 

  20. Hochberg HM, Kanter D, Houser VP. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience. Pharmacopsychiatry 1995; 28: 253–6

    PubMed  Article  CAS  Google Scholar 

  21. Laird LK, Lydiard B, Morton A, et al. Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed out-patients. J Clin Psychiatry 1993; 54(6): 224–8

    PubMed  CAS  Google Scholar 

  22. Krijzer F, Snelder M, Bradford D. Comparison of the (pro) convulsive properties of fluvoxamine and clomipramine with eight other antidepressants in an animal model. Neuropsychobiology 1984; 12: 249–54

    PubMed  Article  CAS  Google Scholar 

  23. Flett SR, Szabadi E, Bradshaw CM. A comparison of the effects of fluvoxamine and amitriptyline on autonomic functions in healthy volunteers. Eur J Clin Pharmacol 1992; 42: 529–33

    PubMed  Article  CAS  Google Scholar 

  24. Saletu B, Grünberger J, Rajna P. Pharmaco-EEg profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. Br J Clin Pharmacol 1983; 15: 369–84

    CAS  Google Scholar 

  25. Linnoila M, Stapleton JM, George DT, et al. Effects of fluvoxamine, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomie nervous system reactivity in healthy volunteers. J Clin Psychopharmacol 1993; 13(3): 175–80

    PubMed  Article  CAS  Google Scholar 

  26. van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl. 1: 1–9

    Article  Google Scholar 

  27. Spigset O, Granberg K, Hägg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257–63

    PubMed  Article  CAS  Google Scholar 

  28. Härtter S, Wetzel H, Hammes E, et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998; 20: 446–9

    PubMed  Article  Google Scholar 

  29. Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 2000; 14(1): 51–80

    Article  CAS  Google Scholar 

  30. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58 Suppl. 5: 7–14

    Google Scholar 

  31. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994; 1: 57–87

    Article  CAS  Google Scholar 

  32. Solvay Pharmaceuticals Inc. Luvox (Fluvoxamine maleate) tablets 25mg, 50mg and 100mg [online]. 2001 Available from URL: http://www.solvaypharmaceuticals-us.com/ [Accessed 2001 Jul 20]

  33. ZumBrannen T, Lu Z, Chang J, et al. The multiple-dose pharmacokinetics of fluvoxamine in children and adolescents [abstract]. Clin Pharmacol Ther 2001; 69(2): 82

    Google Scholar 

  34. ZumBrunnen T, Lu Z, Chang J, et al. The multiple-dose pharmacokinetics of fluvoxamine maleate in children and adolescents [poster]. Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2001 Mar 6–10; Orlando.

  35. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997; 62: 279–86

    PubMed  Article  CAS  Google Scholar 

  36. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73–8

    PubMed  Article  CAS  Google Scholar 

  37. Xu Z-H, Xie H-G, Zhou H-H. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996; 42: 518–21

    PubMed  Article  CAS  Google Scholar 

  38. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35–9

    PubMed  Article  CAS  Google Scholar 

  39. von-Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125–31

    PubMed  Article  CAS  Google Scholar 

  40. Pastrakuljic A, Tang BK, Roberts EA, et al. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem Pharmacol 1997; 53: 531–8

    PubMed  Article  CAS  Google Scholar 

  41. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4

    PubMed  Article  Google Scholar 

  42. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151–9

    PubMed  Article  CAS  Google Scholar 

  43. Figgitt DP, McClellan KJ. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60: 925–54

    PubMed  Article  CAS  Google Scholar 

  44. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 222–9

    PubMed  Article  CAS  Google Scholar 

  45. Apter A, Ratzoni G, King RA, et al. Fluvoxamine open-label treatment of adolescent inpatients with obsessive- compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 342–8

    PubMed  Article  CAS  Google Scholar 

  46. Macher E, Macciotta B, Castro MJ, et al. Fluvoxamine in adolescents with obsessive-compulsive disorder [abstract]. 11th World Congress of Psychiatry; 1999 Aug 6–11; Hamburg. Geneva: World Psychiatric Association, 1999: 108

    Google Scholar 

  47. Walkup J, Reeve E, Yaruyura-Tobias J, et al. Fluvoxamine in childhood OCD: long-term treatment. Eur Neuropsychopharmacol 1999 Sep 9; 9: 307

    Article  Google Scholar 

  48. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344: 1279–85

    Article  Google Scholar 

Download references

Acknowledgements

The full text article in Paedriatric Drugs 2001; 3(10): 763-781 was reviewed by: L. DeVane, Medical University of South Carolina, Department of Psychiatry, Charleston, South Carolina, USA; R. Findling, Case Western Reserve University, Department of Psychiatry and Pediatrics, Cleveland, Ohio, USA; M.A. Grados, John Hopkins University School of Medicine, Baltimore, Maryland, USA; G. Masi, University of Pisa, Division of Child Neurology and Psychiatry, Pisa, Italy; C.F. Ziervogel, University of Capetown, Department of Psychiatry, Capetown, South Africa.

Author information

Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Susan M. Cheer & David P. Figgitt

Authors
  1. Susan M. Cheer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David P. Figgitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan M. Cheer.

Additional information

The full text of this article was published in Paediatric Drugs 2001; 3 (10): 763–781

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cheer, S.M., Figgitt, D.P. Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents. Mol Diag Ther 16, 139–144 (2002). https://doi.org/10.2165/00023210-200216020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200216020-00006

Keywords

  • Anxiety Disorder
  • Fluvoxamine
  • Social Phobia
  • Cisapride
  • Terfenadine